A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Ancobon Indications, Dosage, Storage, Stability - Flucytosine
Ancobon Indications, Dosage, Storage, Stability - Flucytosine
INDICATIONS AND USAGE
Ancobon is indicated only in the treatment of serious infections
caused by susceptible strains of Candida and/or Cryptococcus.
Candida: Septicemia, endocarditis and urinary system infections
have been effectively treated with flucytosine. Limited trials in pulmonary
infections justify the use of flucytosine.
Cryptococcus: Meningitis and pulmonary infections have been
treated effectively. Studies in septicemias and urinary tract infections are
limited, but good responses have been reported.
With the exception of urinary tract infection, Ancobon should
be used in combination with amphotericin B for the treatment of systemic candidiasis
and cryptococcosis because of rapid emergence of resistance to Ancobon in Candida
and Cryptococcus isolates in patients receving Ancobon alone.
DOSAGE AND ADMINISTRATION
The usual dosage of Ancobon is 50 to 150 mg/kg/day administered
in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided
if the capsules are given a few at a time over a 15-minute period. If the BUN
or the serum creatinine is elevated, or if there are other signs of renal impairment,
the initial dose should be at the lower level (see WARNINGS).
HOW SUPPLIED
Capsules, 250 mg (gray and green), imprinted ANCOBON®
250 ICN, bottles of 100 (NDC 0187-3554-10). Capsules, 500 mg (gray and white),
imprinted ANCOBON® 500 ICN, bottles of 100 (NDC 0187-3555-10).
Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F
- 86°F).
REFERENCE: 1. Shadomy S. Appl Microbiol. June 1969;
17: 871 - 877.
ICN Pharmaceuticals, Inc. Costa Mesa, CA 92626
ICN Pharmaceuticals, Inc. ICN Plaza 3300 Hyland Avenue Costa Mesa, California
92626 714-545-0100 3355497EX04 Rev. March 2003
top
